The Institute of Experimental Medicine comprises two units: the Centre for Experimental Biomodeling and the Preclinical Translational Research Centre.
The Institute conducts experimental studies in compliance with GLP regulations to investigate the mechanisms underlying the onset and development of cardiovascular, blood and endocrine diseases as well as to develop and implement the new medical technologies that improve the quality of prevention, diagnosis and treatment of these diseases.
The Institute conducts preclinical studies to test the safety and efficacy of new drugs using SPF animals, introduces the results of research into clinical practice and training process as part of the translational medicine concept.
Today, the Experimental Medicine Institute has facilities for:
- Assessment of the toxicological profile of drugs (animal condition monitoring, biochemistry, pathology)
- Aseptic surgery in chronic experiments
- Full description of the cardiovascular system functions
Main research projects:
- Targeted drug delivery to the ischemic tissue (particularly, magnetic field-guided delivery)
- Myocardial regeneration after ischemia/reperfusion injury
- Central regulatory mechanisms of blood flow
- Myocardial protection against ischemia/reperfusion injury
- Pharmacological and non-pharmacological cerebral protection against ischemia/reperfusion injury
- Stimulation of myocardial regeneration with mesenchymal stem cells and apoptotic bodies
- Tissue engineering of blood vessels and heart valves
- (Auto) fluorescent imaging of ischemia/reperfusion injury
|The Institute comprises:|
|Centre for Experimental Biomodeling
||Preclinical Translational Research Centre
Centre for Experimental Biomodeling
Address: 15/B Parkhomenko street, St. Petersburg
Tel.: +7 (812) 702-51-68Preclinical Translational Research Centre
Address: 43 Dolgoozernaya street, St. Petersburg